MedPath

Comparison the effect of Shirvan herbal ointment and glucantim drug on the cutaneous leshmaniasis wounds.

Phase 3
Conditions
eishmaniasis.
Body mass index (BMI) pediatric, 85th percentile to less than 95th percentile for age
Z68.53
Registration Number
IRCT20230621058552N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
10
Inclusion Criteria

Confirmed cases of urban leishmaniasis.
Informed consent signed
The diameter of the lesion < 2 cm.
Lesions only in hands and feet.

Exclusion Criteria

Pregnant or lactating women,
Cardiovascular patients,
Lesions on joints and cartilage,
The diameter of the lesions> 2 cm,
Illness period of more than 8 weeks,
Sperotrichoid and chronic lesions,
Using any type of treatment for leishmaniasis in the last month.
Participation in any type of project in the last 2 months

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
At each follow-up, the size of erythema, induration, ulceration and scar (largest diameter times its perpendicular diameter in milliliters) will be recorded. Evaluation of clinical recovery based on the complete re-epithelialization of the lesions as the main measure of treatment effect is performed in the last injection session and the follow-up period (1, 4 weeks and 6 months) on each of the treated lesions. Timepoint: The measurement of the lesion is at the beginning of the study (before the start of the intervention) and 1, 4 weeks and 6 months after the start of taking Shirvan herbal ointment and glucantim medicine. Method of measurement: The lesion surface will be measured using caliper software.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath